The Schall Law Firm has initiated recruitment efforts for a securities fraud class action lawsuit against Vistagen Therapeutics, Inc., targeting investors who purchased company securities during a 20-month window from April 1, 2024 through December 16, 2025. The firm alleges that Vistagen made materially false and misleading statements regarding the development prospects of fasedienol, a drug candidate being evaluated in the PALISADE-2 clinical trial.
According to the lawsuit allegations, Vistagen purportedly overstated the potential for Phase 3 success of fasedienol while simultaneously understating the inherent risks associated with clinical study failures. These alleged misrepresentations are claimed to have induced investors to purchase securities at artificially inflated prices, resulting in quantifiable investor losses when the truth regarding the trial outcomes became known.
Prospective class members who acquired Vistagen securities during the specified period and sustained losses are being urged to contact the Schall Law Firm to participate in the litigation. The firm typically handles securities class actions on a contingency basis, meaning investors would not incur upfront legal fees.